Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora Peyvandi

Showing results (311-320 of 610) with videos related to

Pageof 61
Sort By:
Inflammatory Bowel Diseases|January 4, 2021
Anti-TNF-α Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel DiseasesArmando Tripodi, Luisa Spina, Laura Francesca Pisani, et al.
American Journal of Hematology|June 8, 2012
Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patientsMaria Solimando, Luciano Baronciani, Silvia La Marca, et al.
Thrombosis Research|June 14, 2021
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detectionArmando Tripodi, Erica Scalambrino, Veena Chantarangkul, et al.
Haematologica|January 1, 2009
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpuraRoberta Palla, Silvia Lavoretano, Rossana Lombardi, et al.
Research and Practice in Thrombosis and Haemostasis|September 11, 2023
Anti-emicizumab antibodies do not cross-react with mim8 <i>in vitro</i>Carla Valsecchi, Roberta Gualtierotti, Sara Arcudi, et al.
Journal of Thrombosis and Haemostasis : JTH|September 30, 2020
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand diseaseEugenia Biguzzi, Simona Maria Siboni, Saskia le Cessie, et al.
Hematology (Amsterdam, Netherlands)|July 5, 2025
A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia AJohannes Oldenburg, Charles Hay, Flora Peyvandi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 17, 2025
Qualification Criteria of Gene Therapy for Haemophilia-Opinion of the EAHAD Gene Therapy Working GroupWolfgang Miesbach, Ana Boban, Pratima Chowdary, et al.
Blood|October 24, 2002
Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant proteinStefano Duga, Maria Claudia Montefusco, Rosanna Asselta, et al.
Journal of Thrombosis and Haemostasis : JTH|January 6, 2021
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et alEugenia Biguzzi, Simona Maria Siboni, Saskia le Cessie, et al.
Pageof 61

Showing results (311-320 of 610) with videos related to

Sort By:
Pageof 61
Inflammatory Bowel Diseases|January 4, 2021
Anti-TNF-α Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel DiseasesArmando Tripodi, Luisa Spina, Laura Francesca Pisani, et al.
American Journal of Hematology|June 8, 2012
Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patientsMaria Solimando, Luciano Baronciani, Silvia La Marca, et al.
Thrombosis Research|June 14, 2021
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detectionArmando Tripodi, Erica Scalambrino, Veena Chantarangkul, et al.
Haematologica|January 1, 2009
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpuraRoberta Palla, Silvia Lavoretano, Rossana Lombardi, et al.
Research and Practice in Thrombosis and Haemostasis|September 11, 2023
Anti-emicizumab antibodies do not cross-react with mim8 <i>in vitro</i>Carla Valsecchi, Roberta Gualtierotti, Sara Arcudi, et al.
Journal of Thrombosis and Haemostasis : JTH|September 30, 2020
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand diseaseEugenia Biguzzi, Simona Maria Siboni, Saskia le Cessie, et al.
Hematology (Amsterdam, Netherlands)|July 5, 2025
A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia AJohannes Oldenburg, Charles Hay, Flora Peyvandi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 17, 2025
Qualification Criteria of Gene Therapy for Haemophilia-Opinion of the EAHAD Gene Therapy Working GroupWolfgang Miesbach, Ana Boban, Pratima Chowdary, et al.
Blood|October 24, 2002
Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant proteinStefano Duga, Maria Claudia Montefusco, Rosanna Asselta, et al.
Journal of Thrombosis and Haemostasis : JTH|January 6, 2021
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et alEugenia Biguzzi, Simona Maria Siboni, Saskia le Cessie, et al.
Pageof 61